J Biol Chem, Vol. 275, Issue 12, 9035-9042, March 24, 2000
Comparison of Nucleosome Remodeling by the Yeast Transcription
Factor Pho4 and the Glucocorticoid Receptor*
Florian Then
Bergh
§,
Elizabeth M.
Flinn¶
,
John
Svaren
**,
Anthony P.
Wright¶
, and
Wolfram
Hörz

From the
Institut für Physiologische Chemie,
Universität München,
Schillerstrasse 44, D-80336 München, the ¶ Department of
Biosciences, Karolinska Institute, Novum, S-14157 Huddinge, and
Södertörns Högskola, Box 4101,
S-14104 Huddinge, Sweden
 |
ABSTRACT |
Chromatin reorganization of the PHO5
and murine mammary tumor virus (MMTV) promoters is triggered by binding
of either Pho4 or the glucocorticoid receptor (GR), respectively. In
order to compare the ability of Pho4 and GR to remodel chromatin and
activate transcription, hybrid promoter constructs were created by
insertion of the MMTV B nucleosome sequence into the PHO5
promoter and then transformed into a yeast strain expressing GR.
Activation of either Pho4 (by phosphate depletion) or GR (by hormone
addition) resulted in only slight induction of hybrid promoter
activity. However, simultaneous activation of both Pho4 and GR resulted
in synergistic activation to levels exceeding that of the wild type
PHO5 promoter. Under these conditions, Pho4 completely
disrupted the nucleosome containing its binding site. In contrast, GR
had little effect on the stability of the MMTV B nucleosome. A minimal
transactivation domain of the GR fused to the Pho4 DNA-binding domain
is capable of efficiently disrupting the nucleosome with a Pho4-binding
site, whereas the complementary hybrid protein (Pho4 activation domain, GR DNA-binding domain) does not labilize the B nucleosome. Therefore, we conclude that significant activation by Pho4 requires nucleosome disruption, whereas equivalent transcriptional activation by GR is not
accompanied by overt perturbation of nucleosome structure. Our results
show that the DNA-binding domains of the two factors play critical
roles in determining how chromatin structure is modified during
promoter activation.
 |
INTRODUCTION |
The chromatin organization of a gene is an important determinant
of transcriptional regulation. Different genes employ different strategies to regulate access of the transcriptional apparatus to the
promoter. One class of genes, termed preset genes (1), has
transcription factor-binding sites that are constitutively accessible
to cognate factors. Another class of genes, termed remodeling genes
(2), undergoes a transition at the promoter following activation. In
this case, a transactivator first establishes a foothold either by
binding to an accessible site in the promoter and then subsequently
exposing other binding sites. Alternatively, a transactivator may
recognize and bind to a site even when the site is present in a nucleosome.
The two best characterized promoters in the remodeling class are the
yeast PHO5 promoter (3) and the
MMTV1 LTR (2, 4). Phosphate
starvation activates the PHO5 gene through binding of a
basic-helix-loop-helix protein, Pho4, to two sites within the
PHO5 promoter region. A second factor, Pho2, interacts with
Pho4 and increases the affinity of Pho4 for its binding sites (5, 6).
It is largely dispensable when Pho4 is overexpressed (7). Activation of
the PHO5 promoter is accompanied by the disruption of four
positioned nucleosomes, and many requirements for this remodeling have
been defined (3).
Both the glucocorticoid receptor (GR) and nuclear factor I (NFI) are
essential for activation of the MMTV LTR in response to
glucocorticoids. It has become apparent that activation of the promoter
proceeds in two steps (8, 9). The first step involves the binding of GR
to sites contained within the second nucleosome upstream of the site of
transcriptional initiation (the B nucleosome). A localized change in
chromatin structure then allows binding of NFI to its site within this
nucleosome. Affinity of GR for its binding site within a nucleosome is
only marginally lower (about 3-fold) than its affinity for a
non-nucleosomal binding site (10, 11). In contrast, NFI is not capable
of binding to its target when contained in a nucleosome (12). This simple model, the facilitation of NFI binding by GR-mediated nucleosome disruption, was subsequently modified, when Truss et al.
(13) showed that the B nucleosome persists following receptor binding in vivo. This observation was consistent with similar
results obtained in earlier in vitro studies, showing that
GR can bind to a nucleosome without disrupting it (14), but the precise composition of the B nucleosome in the activated MMTV promoter remains
undefined (15). Nonetheless, the B nucleosome appears to be subtly
modified during receptor binding, as demonstrated by a localized
increased accessibility to restriction nucleases (13). The altered
nucleosome allows simultaneous binding of GR and NFI, something never
observed with free DNA (10). Therefore, the model of MMTV activation
has evolved from requiring nucleosome removal to tolerating the
presence of a conformationally changed nucleosome, and finally to
requiring the persistence of the nucleosome as an essential component
of the activation mechanism.
Much of the MMTV LTR regulation has been reconstructed in yeast
(16, 17). Originally, constitutively active derivatives of GR (lacking
the hormone-binding domain) were shown to activate transcription in
yeast (18). It was later shown that hormone-dependent gene
activation could be obtained in yeast cells expressing the intact GR or
derivatives containing the ligand-binding domain (19-21). Further
refinement of the yeast experiments has made it possible to demonstrate
a synergy between GR and NFI activation, which was dependent on the
presence of a modified nucleosome in the MMTV promoter (16, 17).
In the present work, we have attempted to compare directly the
chromatin remodeling inherent in the PHO and the MMTV
system. To that end, we have generated hybrid PHO5 MMTV
promoter constructs that include the nucleosomes remodeled in
PHO5 and the B nucleosome of the MMTV LTR. The purpose of
this study was to perform a side by side comparison of how these
nucleosomes respond to binding of either GR or Pho4. Our results
suggest that nucleosome stability and the DNA-binding domain of the
transactivator both play important roles in determining the mechanism
of chromatin modification.
 |
EXPERIMENTAL PROCEDURES |
Yeast Strains and Media--
The Saccharomyces
cerevisiae strains used in this study were AH220 (a,
trp1, his3-11, leu2-3,
leu2-112, pho5, pho3) (22) and AH240,
a pho4::URA3 derivative of AH220 and
YS33 (23). Yeast strains were grown in YNB medium supplemented with the
required amino acids (high phosphate conditions = repressive) or
in phosphate-free synthetic medium (= activating) (24). Glucocorticoid
induction was accomplished by addition of 10 µM
deoxycorticosterone (DOC) to the medium. Combined induction by hormone
and phosphate depletion was achieved by adding DOC to cultures growing
in YNB for at least 7 h and then transferring the cells to
phosphate-deficient medium supplemented with DOC. After 10-15 h, cells
were analyzed for activity or their chromatin organization.
Plasmids--
The construction of the
PHO5-lacZ reporter plasmid (pPHO5-Z)
was described previously (25). The wild type PHO5 promoter and variants thereof containing the MMTV B nucleosome or a GRE are
schematically depicted in Fig. 1. DNA corresponding to the MMTV B
nucleosome was generated as a 176-base pair PCR fragment derived from
position
222 to
46 of pMMTV-CAT (26) using primers A
(5'-TTTGCTCGAGCTTGCG GTTCCC-3') and B (5'-ATAACCATGGACATAAGAC TTGGAT-3'). pP5-M1 was generated by inserting the MMTV B nucleosome as
an XhoI/NcoI fragment into the PHO5
promoter at newly generated XhoI and NcoI sites
at
344 to
338 and
178 to
172, respectively (see Fig. 1). pP5-M2
was generated by inserting the same fragment into XhoI and
NcoI sites generated by inserting the following sequence
between positions
169 and
168 of the PHO5 promoter (XhoI and NcoI sites underlined):
TCGAGNNNNCCATGGTC GAGAATTGTCAC. The same vector
was also used to create pP5-GRE-Z by inserting a double-stranded DNA
oligonucleotide (GAGCTCGAGGCCTTATGGTTACAAACT GTTCTTAAA
ACCATGGCCA) after cleavage with XhoI and
NcoI.
pGH-N795, a GR expression plasmid, was constructed from pG-N795 (20), a
gift of D. Picard, by replacing TRP1 with the
HIS3 marker. pRS424-NFI, an NFI expression plasmid, was
constructed from pBSSK+ (27), a gift of S. Gasser, by inserting the NFI cDNA sequence into pRS315-PGK (28) and subsequently transferring the entire expression cassette into pRS424. The Pho4
act-tau1 expressing plasmid YEpPho4
act-tau1 was constructed from
YEpPho4
act (designated YEpP4
2 in Ref. 23) by inserting a PCR
fragment from the human glucocorticoid receptor cDNA with the tau1
domain (amino acids 187-244) (29) and a 5' EcoRI site as
well as a 3' BamHI site into BamHI and
EcoRI digested YEpPho4
act. Pho4 derivatives containing
the GR DNA-binding domain were created from YCpPho4 and YCpPho4
act
(designated YCpP4 and YCpP4
2, respectively, in Ref. 23) by replacing
the Pho4 basic-helix-loop-helix domain by the GR DNA-binding domain.
The two primers GTACTCGAG TCAGTGTTTTCTAATGGG and TTATCGATCA TTTG
TTAGGATTTTCCGAAGTG were used to generate a PCR fragment from pGH-N795
as template. The fragment contains the codons for amino acids 407-536
of GR and an adjacent in frame stop codon and was inserted into the
XhoI- and ClaI-digested X variants of
YCpPho4 and YCpPho4
act to yield YCpPho4-GRDBD and YCpPho4
act-GRDBD. The X variants of these
DNAs contain a mutation at position 740 of the coding sequence (GAG
instead of GTG) that generates a unique XhoI site at that position.
Functional Assays and Chromatin Analysis--
-Galactosidase
activity measurements (25), nuclei preparation (30), restriction
nuclease, and DNase I digestion of isolated nuclei (24) were performed
as described previously. All activity values shown are the average of
at least three independent measurements (S.D. <20%).
Western Blotting--
Yeast extracts were prepared as described
by Horvath and Riezman (31). SDS-polyacrylamide gel electrophoresis for
Western blotting was performed using 12.5% polyacrylamide resolving
gels (102 × 72× 0.75 mm) as described previously (32). Primary
antibodies raised against the Pho4 DNA-binding domain were a kind gift
of C. Goding. Secondary anti-rabbit IgG antibodies were detected by
chemiluminescence (32).
 |
RESULTS |
Synergistic Activation of Hybrid PHO5-MMTV Promoter Constructs by
Pho4 and GR--
Hybrid promoter constructs were created to compare
directly aspects of chromatin modulation by GR and Pho4. In one
construct, nucleosome
2 of the PHO5 promoter was replaced
with the MMTV B nucleosome (pP5-M1), and in another, the B nucleosome
was inserted into the full-length PHO5 promoter (pP5-M2, see
Fig. 1). The hybrid promoter constructs
were introduced as lacZ fusions into yeast strains that also
contained a plasmid expressing the intact GR (20). Activation of
PHO5 UAS elements and glucocorticoid response elements (GRE)
contained within the B nucleosome could be achieved by growth in medium
lacking phosphate and by addition of hormone, respectively.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
Hybrid PHO5-MMTV promoter
variants. The chromatin structure at the wild type (wt)
PHO5 promoter under noninduced (+Pi) and induced
( Pi) conditions is shown at the top.
Nucleosomes 1, 2, 3, and 4 are disrupted upon activation. The
small circles mark UASp1 (open) and UASp2
(solid), which are Pho4-binding sites found by in
vitro and in vivo footprinting experiments. The
positions are listed relative to the coding sequence (solid
black). T denotes the TATA box. The three
PHO5-MMTV promoter variants analyzed here are shown
underneath. The hatched circle denotes the MMTV B
nucleosome, either replacing the PHO5 nucleosome 2
(pP5-M1) or inserted as an extra nucleosome between PHO5
nucleosomes 1 and 2 (pP5-M2) as described under "Experimental
Procedures." In pP5-GRE, the PHO5 nucleosome 2 was
replaced by a GRE.
|
|
We first tested the substitution construct in which the B nucleosome
replaces nucleosome
2 (pP5-M1), which removes one of the
PHO5 UAS elements. The resulting promoter responds weakly to
hormone addition and is almost refractory to activation by phosphate
starvation (Fig. 2A). However,
the combination of the two conditions leads to substantial activity
that is comparable to that of the wild type promoter. In contrast, a
promoter construct in which nucleosome
2 was replaced by only a GRE
not contained in a nucleosome (pP5-GRE, see Fig. 1) is more strongly
induced by low phosphate conditions, activity increases from 1.2 to 8% (Fig. 2B). The further induction resulting from the addition
of hormone is only 4-5-fold, however. This contrasts with the 60-fold induction by hormone if the hormone-responsive elements are contained in a nucleosome (Fig. 2A).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Activation of PHO5 promoter
variants containing the MMTV B nucleosome or a GRE. The activities
of pP5-M1 (A) and pP5-GRE (B) as lacZ
fusions in the yeast strain AH220 before and after DOC addition and/or
phosphate depletion are shown. Solid bars indicate high
phosphate, and gray bars indicate no phosphate conditions.
100% activity is defined as the activity of the wild type
PHO5 promoter induced by phosphate starvation. The promoter
structure is shown schematically underneath in both cases (compare Fig.
1).
|
|
The PHO5 promoter variant with an added B nucleosome that
does not replace nucleosome
2 (pP5-M2) allows side by side comparison of chromatin remodeling of the PHO5 nucleosome
2 and the
MMTV B nucleosome (see below). Interestingly, the addition of the B nucleosome almost completely prevents activation of the promoter by
phosphate depletion in the absence of hormone (Fig.
3). However, with both signals present,
added hormone and phosphate depletion, activation is almost 50%
greater than that of the wild type PHO5 promoter (Fig. 3).
These results demonstrate very strong synergistic activation by Pho4
and GR with multiple promoter constructs.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
Activation of a PHO5
promoter variant with an extra MMTV B nucleosome. The
activity of pP5-M2 in the yeast strain AH220 before and after DOC
addition and/or phosphate depletion is shown. Solid bars
indicate high phosphate, and gray bars indicate no phosphate
conditions. 100% activity is defined as the activity of the wild type
PHO5 promoter induced by phosphate starvation. The promoter
structure is shown schematically underneath (compare Fig. 1).
|
|
Chromatin Transitions at a Hybrid PHO5-MMTV Promoter--
In order
to investigate the chromatin transition of the hybrid
PHO5-MMTV promoter, we analyzed nuclease accessibility of
the PHO5 promoter variant with an additional B nucleosome.
We first monitored the effects of phosphate depletion in the absence of hormone. As shown in Fig. 4, the
accessibility of restriction sites within and around the B nucleosome
increases somewhat as a consequence of activation through the two
Pho4-dependent UAS elements. Opening is limited, however,
as shown by the SacI site, the accessibility of which
increases from <5 to 20%. This is consistent with the low activity of
the promoter when only the phosphate depletion signal is active (5% of
fully induced level, see Fig. 2). In contrast, the PHO5
nucleosome
2 is fully disrupted as illustrated by a ClaI
accessibility of more than 90% (see below).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of phosphate depletion on the
accessibility of restriction sites at the pP5-M2 promoter. Nuclei
isolated from the yeast strain AH220 harboring the pP5-M2 plasmid,
grown under high or no phosphate conditions, were treated with 50 units
(odd-numbered lanes) or 200 units (even-numbered
lanes) of the indicated restriction enzyme for 30 min at 37 °C.
In order to monitor the extent of cleavage, DNA was isolated, cleaved
with EcoRV and PvuII, analyzed on a 1.5% agarose
gel, blotted, and hybridized with an upstream pBR322
EcoRV/BamHI fragment. The diagram at the
bottom depicts the positions of the indicated restriction
sites with respect to the nucleosomal organization of the repressed
promoter. In all cases, the appearance of the intact
EcoRV/PvuII fragment (upper band)
signifies protection and the lower band accessibility of the indicated
restriction site.
|
|
The combined effect of phosphate depletion and glucocorticoid addition
on the chromatin structure of the hybrid promoter is depicted in Fig.
5. The ClaI site, which had
been fully accessible even in the absence of hormone, remains 90%
accessible. Unexpectedly, however, there is almost no effect by the
added hormone on sites within and around the B nucleosome. This
contrasts with the dramatic effect of hormone on transcriptional
activation, which increases approximately 20-fold under these
conditions. Apparently, the receptor hormone complex is capable of
activating transcription through the GREs in the B nucleosome without
disrupting its structure as monitored by our protection assay. The
chromatin structure of the hybrid promoter was also analyzed by DNase I
digestion experiments (Fig. 6). The
pattern confirms the disruption of the PHO5 nucleosomes
upstream of the B nucleosome and again demonstrates the relative
stability of the B nucleosome, even after hormone addition. DNase I
digestion of free DNA (right panel in Fig. 6) shows that in
the chromatin digests, protection of the DNA contained in the B
nucleosome is not a property of just the DNA itself but of its
chromatin organization.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of hormone addition on the
accessibility of restriction sites at the pP5-M2 promoter. Yeast
strain AH220 harboring the pP5-M2 plasmid was grown under no phosphate
conditions in either the presence or absence of DOC as indicated.
Nuclei were then isolated and treated with 50 units (odd-numbered
lanes) or 200 units (even-numbered lanes) of the
indicated restriction enzyme for 30 min at 37 °C. DNA was isolated,
cleaved with EcoRV, and analyzed as in Fig. 3. The diagram
at the bottom depicts the positions of the indicated
restriction sites with respect to the nucleosomal organization of the
repressed promoter. The parent 1.85-kilobase pair EcoRV
fragment contains an additional ClaI site in the
lacZ part (unlike the parent 0.82-kilobase pair
EcoRV/PvuII fragment of Fig. 4). This explains
the additional band in the ClaI digests of lanes
1-4 just below the parent band at the top. The sum of
these two bands in relation to the lower band signifies the degree of
protection of the ClaI site in nucleosome 2.
|
|

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 6.
DNase I analysis shows incomplete nucleosome
disruption for the activated hybrid PHO5-MMTV
promoter. Yeast strain AH220, harboring the pP5-M2 plasmid, was
grown either in the presence of phosphate and absence of hormone
(lanes 1-4) or in the absence of phosphate and the presence
of hormone (lanes 5-7). Nuclei were isolated and treated
with 1 (lane 1), 2 (lanes 2 and 7), 4 (lanes 3 and 6), and 8 (lanes 4 and
5) units/ml DNase I for 20 min at 37 °C, and afterward
DNA was isolated. In lanes 8-11, free DNA from the AH220
strain harboring the pP5-M2 plasmid was digested with DNase I (1, 0.5, 0.25, and 0.125 units/ml, respectively). All DNA was subsequently
digested with HindIII, analyzed on a 1.5% agarose gel,
blotted, and hybridized with the upstream
HindIII/BamHI fragment. Double digests of
purified genomic DNA with HindIII and either
ClaI, XhoI, or NcoI serve as markers.
The diagram at the bottom depicts the chromatin organization
of the repressed promoter with the B nucleosome as a hatched
circle (compare Fig. 1) and restriction sites used as markers. In
the schematic between lanes 4 + 5 and lanes
7 + 8, the B nucleosome is depicted as a solid
rectangle with bordering nucleosomes shown as open
rectangles drawn to scale with the gel.
|
|
Is the Relative Stability of the B Nucleosome Due to the Absence of
Nuclear Factor I?--
NFI plays an important role in the activation
of the MMTV LTR both in mammalian cells (33, 34) and when it is
reconstituted into yeast (6). There is strong synergy between NFI and
GR in the activation of chromatin templates. In order to find out if
the stability of the B nucleosome in the context of the PHO5 promoter was due to the absence of NFI in our system, we introduced an
NFI expression plasmid into our strains and analyzed the effects on
transcriptional activation and chromatin structure.
NFI augmented glucocorticoid-dependent promoter activity,
especially at high phosphate conditions. Activity increased from 8 to
25% at high phosphate and from 144 to 150% at low phosphate conditions when NFI was expressed (compare Fig. 3). However,
examination of the stability of the B nucleosome under these conditions
revealed no effect due to expression of NFI. The B nucleosome remained as stable in the presence of NFI as in its absence when assayed by
restriction accessibility measurements (Fig.
7). We conclude therefore that the
stability of nucleosome B in the hybrid promoter is not due to the
absence of NFI.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 7.
NFI does not affect chromatin opening of the
hybrid PHO5-MMTV promoter. Yeast strain AH220
harboring the pP5-M2 plasmid alone (lanes 1-4) or the same
plasmid along with pRS424-NFI (lanes 5-8) was grown in the
absence of phosphate and the presence of hormone. Nuclei were isolated
and treated with 50 units (odd-numbered lanes) or 200 units
(even-numbered lanes) of ClaI (lanes 1, 2, 5, and 6) or SacI (lanes
3 and 4 or 7 and 8) for 30 min at
37 °C. DNA was isolated, cleaved with RsaI, analyzed on a
1.5% agarose gel, blotted, and hybridized with an upstream
RsaI/BamHI fragment. The diagram at the
bottom depicts the positions of the restriction sites with
respect to the nucleosomal organization of the repressed
promoter.
|
|
Does the Glucocorticoid Receptor Lack a Chromatin Opening
Domain?--
Previously, we have shown that the ability of Pho4 to
disrupt chromatin at the PHO5 promoter requires its
transcriptional activation domain (23), and we have so far been unable
to separate functionally transcriptional activation from chromatin
disruption (35). We had also shown that other activation domains like
VP16 are capable of remodeling PHO5 chromatin when they are
fused to the Pho4 DNA-binding domain (23). Because GR transactivates without substantially remodeling a GRE-containing nucleosome, it was
conceivable that its activation domains cannot disrupt chromatin. In
order to test this possibility, we generated a hybrid protein
containing the Pho4 DNA-binding domain (Pho4
act) and the minimal
N-terminal activation domain of GR, the tau1 core domain (29) to give
Pho4
act-tau1 (see Fig. 8).
The hybrid activator was introduced into a yeast strain lacking
endogenous Pho4, and its ability to transactivate and modulate chromatin structure was monitored. The Pho4 GR hybrid protein gave
strong transactivation, which reached levels similar to those attained
by native Pho4. Furthermore, the hybrid protein was fully capable of
disrupting nucleosome
2 (Fig. 8). The
effect of the tau1 domain is not simply due to a stabilizing effect on
Pho4
act and thereby increases a potential chromatin opening activity
of the Pho4 DNA-binding domain. This possibility was ruled out by Western analysis that demonstrated that Pho4
act and Pho4
act-tau1 are expressed to very similar levels (Fig.
9). Therefore, the absence of disruption
of the B nucleosome by GR is not due to the absence of an activity in
GR capable of disrupting chromatin.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 8.
The GR tau1 domain is capable of disrupting
the wild type PHO5 promoter when recruited to the
Pho4-binding sites. The yeast strain AH240 (pho4),
harboring the wild type PHO5 promoter on the
pPHO5-Z plasmid and expressing either Pho4 act or
Pho4 act-tau1, was grown in the absence of phosphate. Isolated nuclei
were digested with ClaI and analyzed as in Fig. 3. The
construction of Pho4 act-tau1 from the human glucocorticoid receptor
(hGR) cDNA and Pho4 act is shown schematically at the
top of the figure. T1 and T2 indicate
the two transactivation domains; DNA indicates the
DNA-binding domain, and Steroid indicates the
hormone-binding domain of GR. bHLH denotes the
basic-helix-loop-helix DNA-binding domain of Pho4, and the location of
the activation domain in full-length Pho4 is indicated at the
bottom.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 9.
Analysis of
Pho4 act-tau1 and
Pho4 act expression levels by Western
blotting. Whole cell extracts from AH240 (pho4) cells,
expressing either Pho4 act or Pho4 act-tau1 that were used in Fig.
8, were analyzed on 12.5% SDS-polyacrylamide gels. Proteins were
blotted and detected with antibodies against the Pho4 DNA-binding
domain as described under "Experimental Procedures."
|
|
The Differential Ability of Pho4 and GR to Disrupt Chromatin Does
Not Reside in Their Activation Domains--
After analyzing a
transactivator containing the Pho4 DNA-binding domain and the GR tau1
core transactivation domain, we created the reciprocal construct by
replacing the Pho4 DNA-binding domain with the corresponding domain
from GR (YCpPho4-GRDBD). In addition, we generated a
truncated hybrid protein lacking the Pho4 activation domain
(YCpPho4
act-GRDBD). Expression of Pho4-GRDBD
resulted in strong activation of the hybrid PHO5-MMTV
promoter with the extra B nucleosome (130% at
Pi
conditions, Table I), which is almost
identical to the activity obtained with native GR (144%, see Fig. 3).
As expected, this activation depended entirely on the integrity of the
Pho4 activation domain. In its absence, only background activity of the
reporter was obtained (Table I).
View this table:
[in this window]
[in a new window]
|
Table I
LacZ activity and accessibility to restriction nucleases of pP5-M2
in the yeast strain AH220
The strain contained in addition either the chimeric proteins
Pho4-GRDBD or Pho4 act-GRDBD. 100% activity is
defined as the activity of the wild type PHO5 promoter
induced by phosphate starvation.
|
|
Although Pho4-GRDBD contains the Pho4 activation domain,
its effect on the B nucleosome is indistinguishable from that of either
native GR or Pho4
act-GRDBD. Limited opening was obtained with both proteins (Table I) very similar to what had been obtained with GR as shown in Figs. 5 and 6. Given that the two proteins can
activate to similar levels yet differ strikingly in their ability to
open up chromatin demonstrates that the inability of GR to disrupt the
B nucleosome does not reside in its activation domain.
 |
DISCUSSION |
The most important outcome of the present study is the finding
that Pho4 and GR differ very much in the way they affect nucleosome structure during activation. The two factors have quite similar effects
on transcriptional activation. However, Pho4 disrupts nucleosome
structure in a much more profound fashion than GR. Upon activation, the
endogenous nucleosomes of the PHO5 promoter became
completely disrupted as shown by their accessibility to restriction
nucleases and DNase I. In contrast, the B nucleosome is virtually
unaffected by the presence of the receptor-hormone complex as judged by
the same criteria.
The relative stability of the B nucleosome is not unique to the
PHO5 context. In mammalian cells, the B nucleosome also
undergoes only a subtle change in structure following activation. Truss et al. (13) have shown that the nucleosome persists upon
hormone-dependent activation of the promoter, albeit in an
altered form that allows the simultaneous binding of GR and NFI. They
have proposed that an important role of the nucleosome is to actually
enable simultaneous binding of NFI and GR, because the two factors
cannot bind to free DNA together (36). Transposition of the entire MMTV
LTR into yeast has been shown to reconstruct many of the properties of
the system. Again only subtle perturbations of the chromatin structure
occur upon activation (16, 17).
The differential effects exerted by Pho4 and GR on chromatin structure
are apparently dictated by differences in how these two factors
interact with their cognate sites. Pho4 binds to its site throughout
two turns of DNA (37), suggesting that binding would not be possible
when the DNA is tightly complexed to a histone octamer. Accordingly,
Pho4 has a much lower affinity for its binding site within a nucleosome
as compared with free DNA. We have shown this to be the case in
vivo (23), and in our in vitro footprint experiments, we have never detected complexes between Pho4 and nucleosomes.2 In contrast, GR
binds quite well to nucleosomes, and the difference in its affinity for
target sites in free DNA compared with a nucleosome is only about
3-fold (10, 11). GR binds to two distinct motifs in the DNA exposed on
the same helical surface and therefore can access its target site
within a nucleosome.
There is considerable evidence that transactivators can alter the
equilibria between nucleosomal and nucleosome-free states in chromatin
(38, 39). A factor like Pho4, which can stably bind only to free sites,
would be expected to shift the equilibria toward the nucleosome-free
state. In this case, extensive disruption might facilitate binding of
Pho2, the other transcription factor required for PHO5
activation, and also interactions between proteins bound to the
upstream and downstream elements of the promoter. In contrast, such
equilibria would presumably be only marginally shifted by GR, which
binds nucleosomal target sites almost as well as nucleosome-free target
sites. Furthermore, the persistence of an altered nucleosome plays a
positive role in facilitating synergy between GR and NFI (40).
Although binding of Pho4 and GR has very different consequences in our
experiments, we could demonstrate that GR does possess an activation
domain that is capable of disrupting nucleosomes when it is fused to
the Pho4 DNA-binding domain. It is possible that this domain within GR
is utilized in other GR target promoters to cause chromatin disruption.
However, this result also indicates that the DNA-binding domain makes
an independent contribution to chromatin disruption. This conclusion
was confirmed by the observation that the Pho4 activation domain has no
effect on B nucleosome stability when fused to the DNA-binding domain
of GR.
One of the most notable aspects of the hybrid PHO5-MMTV
promoters is the profound synergy observed upon activation of both Pho4
and GR. It is striking that activation by either pathway alone gave
very little activity, especially since the hybrid constructs retain
many binding sites for both Pho4 and GR. One general feature of the
nucleosomal organization of promoters seems to be to keep the repressed
levels very low with very little detrimental effect on the activated
levels. This flexibility of the nucleosome has been documented both
in vivo and also by in vitro transcription systems using chromatin templates (41). Our results suggest that the
repressed B nucleosome that is not bound by GR may exert a generally
repressive effect on adjacent promoter regions. Conversely, binding of
GR to multiple sites on the B nucleosome cannot adequately activate
transcription when this nucleosome is surrounded by the nucleosome-repressed PHO5 promoter.
Several important characteristics of the two regulated gene systems,
PHO5 and MMTV LTR, have become apparent from their direct comparison within the PHO5 promoter context. Our results
indicate that modification of chromatin structure during promoter
activation has evolved as a complex interplay between nucleosome
stability, transactivation domains, and DNA-binding domains. The
variations on these themes exhibited by the PHO5 and MMTV
promoters indicate that nucleosomes are flexible structures that
mediate both repression and synergistic activation and have established
these systems as valuable paradigms for the analysis of how chromatin
structure participates in the regulation of eukaryotic promoters.
 |
ACKNOWLEDGEMENTS |
We thank D. Picard and S. Gasser for gifts of
plasmids, C. Goding for antibodies against the Pho4 DNA-binding domain,
and D. Blaschke for expert assistance.
 |
FOOTNOTES |
*
This work was supported by European Commission Human Capital
and Mobility Network Grant ERBCHRXCT940447, by Deutsche
Forschungsgemeinschaft Grant SFB190, by Fonds der Chemischen Industrie
(to W. H.), by Swedish Cancer Fund Grant 3831-B97-02YBB (to
A. P. W.), and by a NATO Postdoctoral fellowship from the National
Science Foundation (to J. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Neurology, Klinikum Grosshadern,
Marchioninistrasse 15, D-81377 München, Germany.
**
Present address: Dept. of Pathology, Washington University School
of Medicine, St. Louis, MO 63110-1093.

To whom correspondence should be addressed. Tel.: 89-5996 420;
Fax: 89-5996 440; E-mail: Hoerz@bio.med.uni-muenchen.de.
2
J. Svaren and W. Hörz, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
MMTV, murine mammary
tumor virus;
GR, glucocorticoid receptor;
LTR, long terminal repeat;
NFI, nuclear factor I;
DOC, deoxycorticosterone;
PCR, polymerase chain
reaction;
GRE, glucocorticoid response element;
UAS, upstream
activating sequence.
 |
REFERENCES |
| 1.
|
Krude, T.,
and Elgin, S. C. R.
(1996)
Curr. Biol.
6,
511-515[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Hager, G. L.,
Smith, C. L.,
Svaren, J.,
and Hörz, W.
(1995)
in
Chromatin Structure and Gene Expression
(Elgin, S. C. R., ed)
, pp. 89-103, Oxford University Press, Oxford
|
| 3.
|
Svaren, J.,
and Hörz, W.
(1997)
Trends Biochem. Sci.
22,
93-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Beato, M.
(1996)
J. Mol. Med.
74,
711-724[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Barbaric, S.,
Münsterkötter, M.,
Goding, C.,
and Hörz, W.
(1998)
Mol. Cell. Biol.
18,
2629-2639[Abstract/Free Full Text]
|
| 6.
|
Barbaric, S.,
Münsterkötter, M.,
Svaren, J.,
and Hörz, W.
(1996)
Nucleic Acids Res.
24,
4479-4486[Abstract/Free Full Text]
|
| 7.
|
Fascher, K. D.,
Schmitz, J.,
and Hörz, W.
(1990)
EMBO J.
9,
2523-2528[Medline]
[Order article via Infotrieve]
|
| 8.
|
Richard-Foy, H.,
and Hager, G. L.
(1987)
EMBO J.
6,
2321-2328[Medline]
[Order article via Infotrieve]
|
| 9.
|
Archer, T. K.,
Lefebvre, P.,
Wolford, R. G.,
and Hager, G. L.
(1992)
Science
255,
1573-1576[Abstract/Free Full Text]
|
| 10.
|
Piña, B.,
Brüggemeier, U.,
and Beato, M.
(1990)
Cell
60,
719-731[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Perlmann, T.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3884-3888[Abstract/Free Full Text]
|
| 12.
|
Candau, R.,
Chavez, S.,
and Beato, M.
(1996)
J. Steroid Biochem. Mol. Biol.
57,
19-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Truss, M.,
Bartsch, J.,
Schelbert, A.,
Hache, R. J. G.,
and Beato, M.
(1995)
EMBO J.
14,
1737-1751[Medline]
[Order article via Infotrieve]
|
| 14.
|
Perlmann, T.,
and Wrange, O.
(1988)
EMBO J.
7,
3073-3079[Medline]
[Order article via Infotrieve]
|
| 15.
|
Fragoso, G.,
Pennie, W. D.,
John, S.,
and Hager, G. L.
(1998)
Mol. Cell. Biol.
18,
3633-3644[Abstract/Free Full Text]
|
| 16.
|
Chavez, S.,
Candau, R.,
Truss, M.,
and Beato, M.
(1995)
Mol. Cell. Biol.
15,
6987-6998[Abstract]
|
| 17.
|
Chavez, S.,
and Beato, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2885-2890[Abstract/Free Full Text]
|
| 18.
|
Schena, M.,
and Yamamoto, K. R.
(1988)
Science
241,
965-967[Abstract/Free Full Text]
|
| 19.
|
Wright, A. P.,
Carlstedt-Duke, J.,
and Gustafsson, J. A.
(1990)
J. Biol. Chem.
265,
14763-14769[Abstract/Free Full Text]
|
| 20.
|
Schena, M.,
Picard, D.,
and Yamamoto, K. R.
(1991)
Methods Enzymol.
194,
389-398[Medline]
[Order article via Infotrieve]
|
| 21.
|
Wright, A. P.,
and Gustafsson, J. A.
(1992)
J. Biol. Chem.
267,
11191-11195[Abstract/Free Full Text]
|
| 22.
|
Rudolph, H.,
and Hinnen, A.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
1340-1344[Abstract/Free Full Text]
|
| 23.
|
Svaren, J.,
Schmitz, J.,
and Hörz, W.
(1994)
EMBO J.
13,
4856-4862[Medline]
[Order article via Infotrieve]
|
| 24.
|
Svaren, J.,
Venter, U.,
and Hörz, W.
(1995)
Methods Mol. Genet.
6,
153-167
|
| 25.
|
Straka, C.,
and Hörz, W.
(1991)
EMBO J.
10,
361-368[Medline]
[Order article via Infotrieve]
|
| 26.
|
Cato, A. C.,
Miksicek, R.,
Schutz, G.,
Arnemann, J.,
and Beato, M.
(1986)
EMBO J.
5,
2237-2240[Medline]
[Order article via Infotrieve]
|
| 27.
|
Santoro, C.,
Mermod, N.,
Andrews, P. C.,
and Tjian, R.
(1988)
Nature
334,
218-224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Kingsman, S. M.,
Cousens, D.,
Stanway, C. A.,
Chambers, A.,
Wilson, M.,
and Kingsman, A. J.
(1990)
Methods Enzymol.
185,
329-341[Medline]
[Order article via Infotrieve]
|
| 29.
|
Dahlman, W. K.,
Almlof, T.,
McEwan, I. J.,
Gustafsson, J. A.,
and Wright, A. P.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1619-1623[Abstract/Free Full Text]
|
| 30.
|
Almer, A.,
Rudolph, H.,
Hinnen, A.,
and Hörz, W.
(1986)
EMBO J.
5,
2689-2696[Medline]
[Order article via Infotrieve]
|
| 31.
|
Horvath, A.,
and Riezman, H.
(1994)
Yeast
10,
1305-1310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Flinn, E. M.,
Busch, C. M.,
and Wright, A. P.
(1998)
Mol. Cell. Biol.
18,
5961-5969[Abstract/Free Full Text]
|
| 33.
|
Bruggemeier, U.,
Rogge, L.,
Winnacker, E. L.,
and Beato, M.
(1990)
EMBO J.
9,
2233-2239[Medline]
[Order article via Infotrieve]
|
| 34.
|
Miksicek, R.,
Borgmeyer, U.,
and Nowock, J.
(1987)
EMBO J.
6,
1355-1360[Medline]
[Order article via Infotrieve]
|
| 35.
|
McAndrew, P. C.,
Svaren, J.,
Martin, S. R.,
Horz, W.,
and Goding, C. R.
(1998)
Mol. Cell. Biol.
18,
5818-5827[Abstract/Free Full Text]
|
| 36.
|
Beato, M.,
Candau, R.,
Chavez, S.,
Mows, C.,
and Truss, M.
(1996)
J. Steroid Biochem. Mol. Biol.
56,
47-59[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Shimizu, T.,
Toumoto, A.,
Ihara, K.,
Shimizu, M.,
Kyogoku, Y.,
Ogawa, N.,
Oshima, Y.,
and Hakoshima, T.
(1997)
EMBO J.
16,
4689-4697[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Svaren, J.,
Klebanow, E.,
Sealy, L.,
and Chalkley, R.
(1994)
J. Biol. Chem.
269,
9335-9344[Abstract/Free Full Text]
|
| 39.
|
Polach, K. J.,
and Widom, J.
(1995)
J. Mol. Biol.
254,
130-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Beato, M.,
Chavez, S.,
and Truss, M.
(1996)
Steroids
61,
240-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Paranjape, S. M.,
Kamakaka, R. T.,
and Kadonaga, J. T.
(1994)
Annu. Rev. Biochem.
63,
265-297[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.